Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.41 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 4/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21963809 | 1.00 | PIK3CD (0.46) | PIK3CDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL22916981 | 0.92 | PIK3CD (0.52) | PIK3CDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL25514814 | 0.92 | PIK3CD (0.52) | PIK3CDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL23011816 | 0.84 | PIK3CD (0.46) | PIK3CDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL5036242 | 0.82 | ATM (0.32) | — | |
| SCHEMBL18347997 | 0.82 | PIK3CD (0.44) | PIK3CDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL14376293 | 0.82 | PIK3CD (0.44) | PIK3CDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL18347996 | 0.82 | PIK3CD (0.44) | PIK3CDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL19869628 | 0.82 | PIK3CD (0.44) | PIK3CDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL15196705 | 0.81 | PIK3CD (0.43) | PIK3CDCHRNB2CHRNA3CHRNA4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-01-20 | — | — | US | disclosed |
| EP-3880664-A1 | LOX INHIBITORS | The Institute of Cancer Research: Royal Cancer Hospital (GB) | 2021-09-22 | — | — | EP | disclosed |
| CN-113365984-A | LOX inhibitors | 癌症研究协会皇家癌症医院 | 2021-09-07 | — | — | CN | disclosed |
| WO-2020099886-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | LOXL1, LOX, LOXL2 | PIK3CD 2549/4885CHRNB2 3882/4885CHRNA3 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.